 4D pharma PLC LON:DDD, NASDAQ:LBPS said pre-clinical research in Germany has shown its bacteria-derived immune-oncology drug worked to enhance the anti-tumour activity of cytotoxic T lymphocytes CTL and CAR-T therapies. The evaluation of animal models was carried out at Philipps-University and Marburgand Universitätsklinikum with the results published in the journal Nature Communications. 